Skip to content

Preventing Celiac Disease by Weaning With Mediterranean Diet

Preventing Celiac Disease by Weaning With Mediterranean Diet

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06184906
Acronym
PEMED
Enrollment
3200
Registered
2023-12-29
Start date
2024-06-15
Completion date
2030-12-31
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weaning Failure

Keywords

Infant Weaning, Mediterranean Diet, Celiac Disease

Brief summary

Background: The introduction of solid foods in alignment with the Mediterranean Diet (MD) post-exclusive milk feeding has been demonstrated to cultivate a lasting affinity for healthy eating during infancy and childhood. Despite this, access to healthy diets remains a challenge for numerous children, particularly in underserved areas. The clinical trial under discussion is set in Scampia, a municipality in Naples, Italy, known for its dense population and socio-economic challenges. This trial, utilizing the Family Pediatrician (FP) system, aims to promote MD nutrition among children in Scampia to potentially prevent or reduce chronic childhood diseases. Study Design: In this pragmatic trial, FPs are utilized as the unit for randomization to administer the intervention. The intervention group will be introduced to an intensified MD-based diet from weaning, incorporating adult-type MD foods, while the control group will follow standard regional dietary guidelines. Dietary adherence and health outcomes are to be periodically monitored, and genetic and microbiome analyses will be conducted using collected saliva and stool samples. Incorporating a Bayesian group sequential design, this trial is structured to conduct interim analyses for efficacy, aligning with local healthcare systems for optimal resource allocation. Conclusion: The study is poised to be methodologically innovative and socially impactful, utilizing existing healthcare frameworks to enhance childhood nutrition in challenging environments. Outcomes from this trial are expected to provide valuable insights into the effects of MD-based nutrition on child health and potentially serve as a model for promoting healthier diets in urban suburbs globally.

Detailed description

Detailed Description: The relationship between systemic chronic inflammation and various chronic diseases, such as obesity, diabetes, cancer, autoimmune, and inflammatory bowel diseases, is well-recognized. Given the economic impact of these diseases on healthcare systems, a comprehensive strategy for risk prevention is imperative. Diet and intestinal dysbiosis are identified as major triggers for systemic chronic inflammation. The MD, characterized by its anti-inflammatory qualities, has also been noted for its positive effects on gut microbiota. The timing of introducing the MD is critical for fostering a healthy microbiota, with early exposure being advantageous. Furthermore, early dietary experiences are crucial in shaping future food preferences. Evidence suggests that responsive feeding practices, such as baby-led weaning, may offer protection against obesity. While the early introduction of the MD in children remains under-researched, its potential protective role against diseases like celiac and inflammatory bowel diseases has been suggested. The PEMED trial, designed to promote MD nutrition among children in Scampia, represents a groundbreaking approach, utilizing a Bayesian cluster randomized clinical trial and the Italian family pediatrician system. This study is unique in its exploration of introducing natural MD foods during infancy and assessing their impact on the establishment of lasting dietary preferences. It leverages the healthcare infrastructure of the Piscinola-Scampia district in Naples for a population-based Pragmatic Clinical Trial, exceeding traditional research design norms. The study is focused on assessing the impact of the MD on the incidence of diseases, employing a Bayesian adaptive sequential approach to allow for ongoing data analysis and adjustments. The PEMED trial's novel approach, combining the early introduction of the MD, population-based surveillance, and an advanced statistical methodology, is poised to set new benchmarks in pediatric research concerning diet and disease prevention. The trial's objectives include evaluating the impact of the MD on the incidence of pediatric diseases, assessing the development of a 'protective' fecal microbiome, and analyzing the persistence of MD dietary choices in children up to the age of 5 years.

Interventions

DIETARY_SUPPLEMENTWeaning by Mediterranean Diet

Introduce solid foods typical of the Mediterranean Diet at weaning of infants

Sponsors

University of Naples
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Data manager are blind to treatment

Intervention model description

FP will be randomly assigned in a parallel 1:1 fashion to one of two intervention groups. A block randomization procedure will be considered for the allocation of FP to the intervention. To ensure unbiased allocation, this sequence will be concealed from investigators. Investigative sites will access the randomization information of enrolled participants through a dedicated online system via the RedCap interface10. In line with ethical considerations, enrolled participants and investigators will not be blinded to the study treatments, as the nature of the dietary intervention does not permit blinding. Therefore, unblinding will not be applicable in this trial. As part of the consent process, participants' permission will be sought to use their data even if they choose to withdraw from the trial. Additionally, participants will be asked for consent to share relevant data with researchers from participating universities or regulatory authorities, where relevant.

Eligibility

Sex/Gender
ALL
Age
1 Months to 10 Months
Healthy volunteers
No

Inclusion criteria

* \- Healthy newborns with a birth weight greater than 2000 grams. * Residence in Municipality 8, Piscinola-Scampia.

Exclusion criteria

* \- Newborns suffering from severe prematurity. * Newborns with congenital malformations. * Newborns afflicted by severe diseases.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Celiac Disease3 to 6 years of ageMonitoring the incidence of Celiac Disease in the study population.
Children growth4 to 6 yearsCalculating the Body Mass Index (BMI kg/m\^2) as a measure of growth, assessing if children's BMI falls within the normal range for their age and sex.

Secondary

MeasureTime frameDescription
Beneficial Microbiome5 to 6 years of ageEvaluating the composition of the microbiome for beneficial characteristics.
Bifidibacteriaceae in the feces5 yearsMeasuring the variation of Bifidobacteria in feces.

Contacts

Primary ContactLUIGI GRECO
ydongre@unina.it3341587925
Backup ContactRENATA AURICCHIO
rRenata Auricchio <r.auricchio@unina.it>+393392507648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026